[go: up one dir, main page]

WO2007130064A8 - Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone - Google Patents

Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone

Info

Publication number
WO2007130064A8
WO2007130064A8 PCT/US2006/017994 US2006017994W WO2007130064A8 WO 2007130064 A8 WO2007130064 A8 WO 2007130064A8 US 2006017994 W US2006017994 W US 2006017994W WO 2007130064 A8 WO2007130064 A8 WO 2007130064A8
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
methods
pyridinylamino
thiazolidinedione
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/017994
Other languages
English (en)
Other versions
WO2007130064A1 (fr
Inventor
Yehudit Dolitzky
Yoseph Avezov
Dina Spivak
Minutza Leibovici
Ben-Zion Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0621551A priority Critical patent/BRPI0621551A2/pt
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to MX2008014298A priority patent/MX2008014298A/es
Priority to PCT/US2006/017994 priority patent/WO2007130064A1/fr
Priority to CNA2006800543976A priority patent/CN101426789A/zh
Priority to CA002647829A priority patent/CA2647829A1/fr
Priority to JP2009509523A priority patent/JP2009536643A/ja
Publication of WO2007130064A1 publication Critical patent/WO2007130064A1/fr
Priority to IL188175A priority patent/IL188175A0/en
Anticipated expiration legal-status Critical
Publication of WO2007130064A8 publication Critical patent/WO2007130064A8/fr
Priority to NO20085124A priority patent/NO20085124L/no
Priority to NO20092362A priority patent/NO20092362L/no
Priority to IL199822A priority patent/IL199822A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un composé isolé de formule (I), ainsi que des procédés permettant de le détecter et de minimiser sa présence dans des compositions pharmaceutiques améliorées à base de maléate de rosiglitazone.
PCT/US2006/017994 2006-05-09 2006-05-09 Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone Ceased WO2007130064A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2009509523A JP2009536643A (ja) 2006-05-09 2006-05-09 ２−ｎ−｛５−［［４−［２−（メチル−２−ピリジニルアミノ）エトキシ］フェニル］メチル］−２，４−チアゾリジンジオン｝−ブタン二酸、製造方法、および、ロシグリタゾンマレアートとの組成物
MX2008014298A MX2008014298A (es) 2006-05-09 2006-05-09 Ácido 2-n-{5-[[4-[2-(metil-2-piridinilamino)etoxi]fenil]metil]-2,4 -tiazolidindiona}butanodioico, metodos de preparacion y composiciones con maleato de rosiglitazona.
PCT/US2006/017994 WO2007130064A1 (fr) 2006-05-09 2006-05-09 Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone
CNA2006800543976A CN101426789A (zh) 2006-05-09 2006-05-09 2－n－{5－[[4－[2－(甲基－2－吡啶氨基)乙氧基]苯基]甲基]－2，4－噻唑烷二酮}丁二酸、其制备方法以及具有马来酸罗格列酮的组合物
CA002647829A CA2647829A1 (fr) 2006-05-09 2006-05-09 Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone
BRPI0621551A BRPI0621551A2 (pt) 2006-05-09 2006-05-09 composto isolado, composição, embalagem vedada, processos para produzir a composição farmacêutica, para preparar a composição farmacêutica ou a embalagem vedada, para validar uma batelada de uma composição farmacêutica e para produzir o composto isolado, método para aumentar a sensibilidade à insulina em um indivíduo humano, e, uso da composição
IL188175A IL188175A0 (en) 2006-05-09 2007-12-17 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
NO20085124A NO20085124L (no) 2006-05-09 2008-12-09 2-n-(-5-[[4-(2-(methyl-2-pyridinylamino)ethoxy]phenly]methyl]-2,4-thaizolidinedione)butanedioic acid, methods of preparation and compositions whit rosiglitazone
NO20092362A NO20092362L (no) 2006-05-09 2009-06-19 2-N-(5-[{4-(2-(metyl-2-pyridinylamino) etoksy] fenyl]metyl}2,4-tiazolidinedion) butanedisyre, fremgangsmater for fremstilling og sammensetninger med rosiglitazon maleat
IL199822A IL199822A0 (en) 2006-05-09 2009-07-13 Sealed package of pharmaceutical composition comprising 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/017994 WO2007130064A1 (fr) 2006-05-09 2006-05-09 Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone

Publications (2)

Publication Number Publication Date
WO2007130064A1 WO2007130064A1 (fr) 2007-11-15
WO2007130064A8 true WO2007130064A8 (fr) 2008-11-13

Family

ID=38668055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017994 Ceased WO2007130064A1 (fr) 2006-05-09 2006-05-09 Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone

Country Status (8)

Country Link
JP (1) JP2009536643A (fr)
CN (1) CN101426789A (fr)
BR (1) BRPI0621551A2 (fr)
CA (1) CA2647829A1 (fr)
IL (2) IL188175A0 (fr)
MX (1) MX2008014298A (fr)
NO (2) NO20085124L (fr)
WO (1) WO2007130064A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013141A2 (fr) * 2008-08-01 2010-02-04 Actavis Group Ptc Ehf Hydrogénosulfate de rosiglitazone essentiellement pur
CN102863436B (zh) * 2012-06-19 2018-02-09 重庆医科大学 噻唑烷二酮类衍生物及其制备和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives

Also Published As

Publication number Publication date
CA2647829A1 (fr) 2007-11-15
BRPI0621551A2 (pt) 2016-08-16
MX2008014298A (es) 2008-11-26
WO2007130064A1 (fr) 2007-11-15
IL199822A0 (en) 2011-07-31
CN101426789A (zh) 2009-05-06
JP2009536643A (ja) 2009-10-15
IL188175A0 (en) 2008-03-20
NO20085124L (no) 2009-02-04
NO20092362L (no) 2009-02-04

Similar Documents

Publication Publication Date Title
WO2005080358A3 (fr) Phosphate de rosiglitazone et formes polymorphes
JP2006512357A5 (fr)
TW200745099A (en) Optically active thiazolidinedione derivatives
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
MXPA01010821A (es) Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
EP1078923A3 (fr) Procédé de préparation de dérivés de benzothiophène
WO2007106879A3 (fr) Procede de preparation de n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide et metabolites associes
BRPI0517396A (pt) preparação oral com melhor biodisponibilidade
WO2007130064A8 (fr) Acide 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione)butanedioique, procedes de preparation et compositions a base de maleate de rosiglitazone
CY2200159T2 (el) 2-ν-{5-[[4-[2-μεθυλ-2-πυριδινυλαμινο)αιθοξυ]φαινυλ]μεθυλ]-2-4-θειαζολιδινοδιονο} βουτανιοδιοϊκο οξυ, μεθοδοι παρασκευης και συνθεσεις με μηλεϊνικη ροζιγλιταζονη
WO2008062244A8 (fr) Polymorphes de bromhydrate de 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-pipérazinyl]-éthyl}-6-chloro-1,3-dihydro-2h-indol-2-one et leurs procédés de préparation
TW200740802A (en) Pharmaceutical composition containing thiazolidinedione compound
AU8428401A (en) The hydrochloride salt of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione
WO2002028857A8 (fr) Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
PT1988085E (pt) Processo para a produção de éster de propionato de 3-[5-[4-(ciclopentiloxi)-2-hidroxibenzoil]-2-[(3- hidroxi-1,2-benzisoxazol-6-il)metoxi]fenilo] e produtos intermédios para o processo
PL385697A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania
WO2008010089A3 (fr) Procédé pour préparer des intermédiaires de la rosiglitazone, rosiglitazone et nouvelles formes polymorphes de celle-ci
HUP0600347A3 (en) Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate
ATE310000T1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
WO2008105326A1 (fr) Procédé de production d'un dérivé de 2-imino-4-thiazolidinone et d'un dérivé de 2,4-thiazolidinedione
WO2009069643A1 (fr) Dispersion solide renfermant de l'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)méthoxy]phényl]-propionique ou l'un de ses sels ou composition comprenant la dispersion solide
WO2010013141A3 (fr) Hydrogénosulfate de rosiglitazone essentiellement pur
EA200700568A1 (ru) Способ получения розиглитазона
WO2003099337A3 (fr) Nouveaux composes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 188175

Country of ref document: IL

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06759444

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2076/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2647829

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200680054397.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020087026795

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/014298

Country of ref document: MX

Ref document number: 2009509523

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008148318

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06759444

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 199822

Country of ref document: IL

ENP Entry into the national phase

Ref document number: PI0621551

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081014